We discuss endocytosis and compartmentalization of metabolic and signaling pathways. Caveolin 3 (CAV3) and polymerase I and transcript release factor (PTRF) are important proteins that ensure shaping of caveolae in muscle cells. We investigated caveolae morphologically by electron microscopy in myotubes obtained from patients with CAV3 mutations and performed functional analyses in fibroblasts from a patient with a mutation in PTRF. Despite the complete clinical picture of a caveolinopathy, we found that caveolae in the CAV3-deficient myotubes were normal in shape and number. Furthermore, we found a difference in uptake of cholera toxin B between PTRFdeficient fibroblasts devoid of caveolae and normal fibroblasts. However, after caveolae were rescued by transfection of PTRF, cholera toxin B uptake did not normalize. We conclude that the presence of caveolae as an anatomic structure is not sufficient to ensure their proper function. Alternatively, the functional properties assigned to caveolae might be mediated by different mechanisms that have yet to be resolved.
caveolae; caveolin; cavin 1/polymerase I and transcript release factor; fluorescein-activated cell sorting; electron microscopy CAVEOLAE ARE VESICULAR STRUCTURES that can open up to the outer cell membrane, where they are identified as flasklike invaginations. Caveolae vary in size between 25 and 100 nm and are encountered on numerous mammalian cell types, such as adipocytes, myocytes, and fibroblasts. Caveolae are characterized by the presence of scaffolding proteins, the most important of which are caveolin and the family of cavins. There are three caveolin proteins. Caveolin 3 (CAV3) is specific for muscle, and caveolin 1 (CAV1) is present on all other caveolae-bearing cell types. There are four cavin proteins. Cavin 1, subsequently named polymerase I and transcript release factor (PTRF), appears to be a very good marker for caveolae, because PTRF binds to CAV1 only when caveolae are fully assembled at the cell membrane (3) . The function of caveolae has not been resolved, but they are probably involved in endocytosis and formation of the t-tubular structure in muscle cells. However, the dynamics of caveolar endocytosis, the cargo transported through caveolae, and the cell type specificity of caveolae are not clear (8) . It has also been shown that caveolae maintain a plasma membrane reservoir to adjust changes in cell volume (15) .
Several diseases are associated with mutations in genes encoding the caveolins and PTRF. Mutation in PTRF results in muscular dystrophy, with the rippling muscle phenomenon, lipodystrophy, hypertrophy of the striated and smooth muscle, cardiac conduction defects, and endocrinological abnormalities (13) . Mutations in CAV3 lead to mild to moderate muscle weakness and muscle rippling, as well as myalgias and, occasionally, cardiomyopathy (limb girdle muscular dystrophy 1A). Mutations in CAV1 are associated with cancer (10) . Whether these diseases and symptoms are caused by the absence of caveolae and subsequent disturbances of endocytosis or whether a role of the affected proteins independent of the anatomic structure of "caveolae" is responsible is unresolved.
We investigated caveolae in human CAV3 and PTRF mutations morphologically and functionally.
MATERIALS AND METHODS
Cells, cell culture, and transfection. Primary myoblasts were isolated from patients with mutations in CAV3 and immortalized as described elsewhere (12) . The cell line established in our laboratory harbored a heterozygous mutation in exon 1 (c.80GϾA, p.R27E). Another cell line derived from a patient with a heterozygous mutation in exon 1 (c.83CϾT, p.P28L) was provided by Dr. Vincent Mouly (Pierre and Marie Curie University, Paris, France). The muscle cells were cultivated in a CO 2 incubator (BBD 6220, Thermo Fischer Scientific, Schwerte, Germany) at 37°C in 5% CO 2 and 96% relative humidity. Skeletal muscle cell growth medium (Provitro, Berlin, Germany) complemented with 10% fetal calf serum (Biochrom, Berlin, Germany), 1.5% GlutaMAX (Gibco/Life Technologies, Darmstadt, Germany), and 40 g/ml gentamicin (Gibco) was used as proliferation medium. Myoblasts were grown to 80 -90% confluence and subsequently switched to differentiation medium [Opti-MEM I (1ϫ), Gibco] for 4 -6 days.
Primary human fibroblasts lacking PTRF (c.362dupT) and fibroblasts from healthy controls (13) were cultured in DMEM (Gibco) supplemented with 10% fetal calf serum and gentamicin (40 g/ml).
At 1 day after they were plated, fibroblasts were transfected by microinjection or lipofection. The plasmid DNA used for the experiments was human PTRF cloned into pEGFP-N3 vector (Clontech Laboratories, Mountain View, CA). We diluted the plasmid DNA in ultrapure water to a final concentration of 0.05 and 1 g/l, respectively. At 1 day after transfection, we controlled protein expression by enhanced green fluorescence protein (eGFP) epifluorescence. For microinjection, we seeded fibroblasts onto culture dishes with a cover glass bottom (FD35, World Precision Instruments, Berlin, Germany). We transfected the cells with a FemtoJet system (Eppendorf, Wesseling-Berzdorf, Germany) combined with the InjectMan NI 2 (Eppendorf). After centrifugation at 4°C for 30 min, we loaded the supernatant immediately onto the capillaries (Femtotip II, Eppendorf). For microinjection into the cytoplasm of fibroblasts, an injection pressure of 150 hPa was used. For lipofection, we plated fibroblasts in six-well plates (TPP, Cotech, Berlin, Germany). To each well, we added 200 l of serum-free DMEM containing 1 l of plasmid DNA and 2 l of transfection reagent (X-tremeGENE HP, Roche, Mannheim, Germany). At 1 day after transfection, we controlled protein expression and calculated the transfection rate (2-5%).
RT-quantitative PCR. After extraction from cultured skin fibroblasts, 500 ng of total RNA were reverse-transcribed into cDNA using the SuperScript III kit (Life Technologies) with random hexamers. RT-quantitative PCR was run in triplicate on a sequence detection system (ABI7700, Applied Biosystems) using SYBR Green (Life Technologies) chemistry with the following oligonucleotide primer pairs: 5=-CGT GGT CAA GAT TGA CTT TGA A-3= (forward) and 5=-CAC AGT GAA GGT GGT GAA GC-3= (reverse) for CAV1, 5=-GAG GAC ATA GTC AAG GTG GA-3= (forward) and 5=-TGT AGC TCA CCT TCC ACA C-3= for CAV3 (reverse), and 5=-AGA TCA AGA AGC TGG AGG T-3= (forward) and 5=-AGC TTC ACT TCA TCC TGG T-3= (reverse) for PTRF. The primers were chosen to comprise all known splice isoforms of the genes. 18S rRNA, GAPDH, and hypoxanthine guanine phosphoribosyl transferase (HPRT) were used as reference genes, as described elsewhere (6) . For calculation of the amplification ratio of test to reference genes using the PCR efficiency-corrected comparative threshold (Ϫ⌬⌬Ct) method (11), we first determined the efficiency of each PCR with a 1:10 standard dilution series.
Cholera toxin subunit B uptake assay. For subsequent immunofluorescence and fluorescence imaging, we plated fibroblasts in eightwell chamber slides (Nunc LabTek, Thermo Fischer Scientific). After 3 days, we incubated the cells for 5, 10, or 15 min at 37°C with Alexa Fluor 555-labeled cholera toxin subunit B (CTxB; Molecular Probes/ Life, Darmstadt, Germany) at a concentration of 200 ng/ml in cell culture medium. Fibroblasts intended for fluorescein-activated cell sorting (FACS) experiments were seeded onto six-well plates. We incubated the cells with Alexa Fluor 488-or 647-labeled CTxB (Molecular Probes) at 37°C and at a concentration of 400 ng/ml in cell culture medium. CTxB incubation times were set to 2, 15, and/or 60 min. For the starving assay, the labeled CTxB was diluted in glucosefree HEPES-buffered Krebs-Ringer solution (1 mM CaCl 2, 5 mM NaOH, 25 mM HEPES, 135 mM NaCl, 3.6 mM KCl, 0.5 mM K2HPO4, and 0.5 mM MgSO4, pH 7.4). Furthermore, we preincubated fibroblasts before CTxB treatment in DMEM including supplements or in glucose-free Krebs-Ringer-HEPES buffer.
Immunofluorescence. Fibroblasts were washed with PBS (Gibco) and fixed in 3.7% formaldehyde-PBS solution for 12 min at room tempera- Fig. 2 . RT-quantitative PCR analysis of relative mRNA copy numbers for CAV1, CAV3, and PTRF. Copy numbers were determined in primary (n ϭ 2) and immortalized (n ϭ 2) myotubes (MT) from controls and CAV3 ϩ/Ϫ patients (n ϭ 2), as well as in PTRF Ϫ/Ϫ (n ϭ 1) and control (n ϭ 1) fibroblasts (FB). Horizontal lines, mean of each triplicate measurement. mRNA ratios are expressed in relative to mRNA copy numbers of GAPDH, hypoxanthine guanine phosphoribosyl transferase (HPRT), and 18S rRNA. Red symbols, mutant cell lines; black symbols, control cell lines. Mutation on the amino acid level is shown. ture (RT). After repeated washing in PBS, the cells were permeabilized with 0.2% Triton X-100 in PBS for 2 min. The cells were washed with PBS and blocked for 30 min with 1% BSA (Carl Roth, Karlsruhe, Germany) in PBS. We incubated the primary antibodies in PBS containing 1% BSA for 60 min at RT. After thorough washing with PBS, the cells were incubated with the secondary antibodies for 60 min at RT in 1% BSA in PBS. After the washing procedure, the nuclei were stained with Hoechst 33342 (Invitrogen/Life Technologies) diluted 1:2,000 in 1% BSA in PBS for 3 min at RT. After a final washing procedure, the samples were mounted in Aqua PolyMount (Polysciences, Eppelheim, Germany). The primary antibodies were as follows: monoclonal antibody to Cav1 (1:200 dilution; sc-53564, Santa Cruz Biotechnology, Heidelberg, Germany) and polyclonal antibody to Cav1 (1:250 dilution; ab2910, Abcam, Cambridge, UK). As secondary antibodies, we used anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Flour 647 (Molecular Probes), each diluted 1:500.
FACS experiments. Before FACS analysis, fibroblasts were washed in PBS and fixed in 3.7% formaldehyde-PBS solution for 12 min at RT. To increase the sample size, we pooled identically treated wells and analyzed them in a flow cytometer (FACSCanto, Becton Dickinson, Sparks, MD). We used FlowJo 10.0.7 software (TreeStar, Ashland, OR) to evaluate the resulting data. For further postprocessing of the FACS data and for statistics, we used R software version 3.1 (12a). FACS gating parameters were set to selectively assess eGFP-positive or -negative cells.
Atomic force microscopy, confocal imaging, and image processing. On the day after microinjection, the fibroblasts were fixed in 3.7% formaldehyde-PBS solution for 12 min at RT. After thorough washing in PBS, the cells were transferred the dish to the atomic force microscope (AFM) stage. We used a Nanowizard II AFM (JPK Instruments, Berlin, Germany) mounted to a confocal laser-scanning microscope (LSM 700, Zeiss, Göttingen, Germany). Prior to each experiment, we applied the thermal noise method to calibrate the cantilever (4). The AFM was operated in contact mode under liquid (PBS). A petri dish heater (JPK Instruments) kept the temperature constant at 25°C. A translucent and uncoated soft silicon nitride cantilever with a silicon tip (Hydra 2R-100N, Applied NanoStructures, Mountain View, CA) was chosen. The cantilever had a nominal spring constant of 0.011 N/m and a resonant frequency of 21 kHz. Immediately after a bright-field image of the cantilever tip and a fluorescence image of the sample were obtained, AFM scanning was started. We acquired the scans at a force set point of 0.3 nN and a line rate of 1 Hz.
The AFM data were processed with JPK Data Processing 4.2 software (JPK Instruments) and Gwyddion software (9) . We removed very few isolated streaks by line interpolation and enhanced the image contrast by slope correction, resulting in image flattening. To visualize fine structures, we fitted a polynomial to the entire height image and subtracted this background slope from the image. Using the cantilever tip as landmark (17), we combined and overlaid confocal and AFM images.
For confocal imaging, we used the Zeiss LSM 700 confocal microscope equipped with a LCI Plan-Neofluar ϫ63/1.3 glycerol immersion lens (Zeiss). For quantification of fluorescence intensities, we obtained 8 -10 images per cell type and treatment using a LD Plan-Neofluar ϫ40/0.6 lens (Zeiss). We processed the fluorescence images with the Fiji distribution of ImageJ (14), adjusting brightness and contrast, removing background noise, and applying Gaussian smoothing. Next, we measured the cumulated fluorescence intensities per image and normalized the result to the respective number of nuclei. Using R software (12a), we calculated the statistical significance of the quantified fluorescence intensities. Finally, we assembled all images and graphs in Adobe Illustrator CS5 software (Adobe Systems, Dublin, Ireland).
Transmission electron microscopy. At 3 days after sorting by FACS, we processed cells for conventional electron microscopy. Adherent fibroblasts and myotubes or FACS-sorted eGFP-positive fibroblasts were fixed for 2 h in 2.5% glutaraldehyde at pH 7.4. Because of the small number of cells, FACS-sorted fibroblasts were resuspended in 10% gelatin and pelleted. The gelatin was solidified at 4°C for 30 min. Subsequently, we sectioned the cell pellet to 1-mm 3 cubes and processed them further for Epon embedding. Adherent and gelatin-embedded cells were postfixed with 1% osmium tetroxide, gradually dehydrated in ethanol, and embedded in Epon resin. Ultrathin sections were cut using an ultramicrotome (Ultracut S, Reichert Division of Leica, Vienna, Austria), stained with uranyl acetate and lead citrate, and observed under a transmission electron microscope (EM 910, Zeiss, Oberkochen, Germany). Images were obtained with a CDD camera (Quemesa, Olympus Soft Imaging Solutions, Münster, Germany) integrated into the imaging software iTEM (version 5.2, Olympus Soft Imaging Solutions).
Selection criteria for quantification of caveolae in myotubes were as follows: 1) contrasted and sharp plasma membrane, 2) fully accessible transverse or longitudinal sections, and 3) lack of strong artifacts from fixation, e.g., vacuoles, extracted organelles, and ruptured cells. As morphological differentiation markers, the presence of more than two nuclei (2) was defined for quantification (Fig. 1B) . For every cell line, 10 -13 myotubes of 1 embedding preparation were analyzed, and Ն600 m of plasma membrane per cell line were quantified. Images at ϫ5,000 magnification were acquired and analyzed with the iTEM software. The length of the plasma membrane and the number of distinct endocytic structures were quantified. Statistical analyses were done using R software version 3.1 (12a). Fig. 3 . Uptake and subcellular localization of cholera toxin subunit B (CTxB) in healthy fibroblasts is distinct from that in fibroblasts devoid of caveolae. After 10 min of incubation with Alexa 555-labeled CTxB, fibroblasts were exposed to antibody to CAV1. Nuclei were stained with Hoechst. In contrast to PTRF
RESULTS AND DISCUSSION
CAV3 mutants in human skeletal muscle lead to severe reduction of CAV3 protein, but caveolae decorate the sarcolemma normally. Serial sections obtained from muscle biopsy specimens from patients with heterozygous mutations in CAV3 (p.P28L and p.R27E, respectively) demonstrate a mild myopathy with a slight increase in connective tissue components and a severe reduction in CAV3 protein expression (Fig. 1A) . Using electron microscopy, we quantified caveolae in human myotubes obtained from the same patients with CAV3 mutations. Myotubes for quantification were carefully selected using predefined criteria (see MATERIALS AND METHODS; Fig. 1, B  and C) . The number of open caveolae in normal myotubes and in myotubes carrying CAV3 mutations was almost identical (Fig. 1D) . The morphology of individual caveolae was also not different between normal and CAV3 mutant myotubes. One could argue that caveolae form nevertheless, because only one CAV3 allele is mutated in autosomal-dominant limb girdle muscular dystrophy 1A. However, the number of caveolae was not reduced accordingly. Apparently, caveolae form even if CAV3 is severely reduced.
Mutation in one structural component of the caveolae (e.g., caveolin or cavin) is not compensated by mRNA upregulation of the other components.
Despite the presence of a heterozygous mutation in CAV3, the CAV3 mRNA copy number did not differ significantly between immortalized CAV3 ϩ/Ϫ and control myotubes (Fig. 2) . The tendency of primary myotubes of the controls toward higher CAV3 mRNA copy numbers varied (ratio 1.2-2.5, depending on the reference gene).
There was no compensation for upregulation of CAV1 and PTRF mRNA copy numbers in mutant CAV3 ϩ/Ϫ myotubes. The PTRF mRNA transcripts in PTRF Ϫ/Ϫ mutant fibroblasts were grossly reduced compared with control fibroblasts, probably due to nonsense-mediated messenger decay secondary to the frame-shift mutation c.362dupT. Depending on the chosen reference gene, CAV1 mRNA transcripts were only inconsistently upregulated (if referred to GAPDH and HPRT) or remained unchanged (if referred to 18S rRNA). CAV3 mRNA transcripts were absent in control and PTRF Ϫ/Ϫ mutant fibroblasts. Taken together, all three proteins seem to participate in formation and function of the caveolae in different contexts and cannot easily compensate for each other.
Uptake of cholera toxin in human PTRF Ϫ/Ϫ fibroblasts is distinct from that in healthy fibroblasts. To gain further insight into the impact of caveolae on endocytosis, we selected human fibroblasts with a mutation in PTRF that are completely devoid of caveolae and compared these with normal fibroblasts (Fig.  1D) (13) . As a model, we chose uptake of CTxB. CTxB is enriched and internalized by caveolae but also diffuses into cells in the absence of caveolae (1, 5) . First, fluorescently labeled CTxB was followed on the single-cell level using confocal microscopy (Fig. 3) . After CTxB uptake, cells were fixed and costained with anti-CAV1 antibody. In healthy PTRF ϩ/ϩ fibroblasts, CAV1 and CTxB colocalized clearly at the membrane and also at intracellular structures. In contrast, PTRF Ϫ/Ϫ fibroblasts displayed a diffuse distribution pattern of CTxB and no colocalization of CAV1 and CTxB (Fig. 3) .
High-throughput FACS analysis is suitable for detection of differences in
CTxB uptake dependent on caveolae. Quantification of CTxB uptake by measurement of fluorescence intensities in confocal images was difficult and rather subjective. We therefore developed an alternative strategy to quantify CTxB uptake not on the single-cell level but, rather, by a high-throughput analysis. We incubated human PTRF ϩ/ϩ and PTRF Ϫ/Ϫ fibroblasts with Alexa 488-CTxB for 15 min and analyzed the cells by FACS. The intensity distribution represented by density curves and box plots showed significant differences in CTxB uptake (Fig. 4A) . Mean intensity was significantly lower in PTRF Ϫ/Ϫ than healthy control fibroblasts (13,885 vs. 24,455, P Ͻ 0.001). Furthermore, characteristic differences in distribution of CTxB uptake were observed between PTRF ϩ/ϩ and PTRF Ϫ/Ϫ fibroblasts, with a distinctive bimodal curve in PTRF Ϫ/Ϫ cells. These results support the notion that caveolae are important for CTxB uptake. We wondered if CTxB uptake was dependent on the duration of CTxB incubation or on cell culture media components and tested multiple conditions (Fig. 4B) . CTxB intensity increased with prolonged incubation of CTxB; thus the intensity distribution slightly shifted toward higher levels. We also modified the media by depleting glucose or serum growth factors. The impact of media modification, however, was negligible. The bimodal curve of CTxB uptake in PTRF Ϫ/Ϫ cells and the differences between PTRF Ϫ/Ϫ and normal fibroblasts remained. Therefore, the differences in subcellular CTxB distributions, as well as the distinct uptake characteristics quantified by FACS, suggest a role of caveolae in CTxB uptake.
Rescue of PTRF in PTRF Ϫ/Ϫ fibroblasts is sufficient to induce de novo formation of caveolae. If the caveolae account for the differences in CTxB uptake, then a PTRF rescue in PTRF Ϫ/Ϫ cells should alter the uptake behavior and the curve shape of FACS analysis should change to that seen in normal fibroblasts. Before analyzing the CTxB uptake, we verified by three different methods that PTRF rescue was sufficient to induce formation of caveolae in PTRF Ϫ/Ϫ fibroblasts. 1) We transfected PTRF Ϫ/Ϫ fibroblasts with eGFP-tagged human PTRF plasmid DNA. At 1 day after transfection, anti-Cav1 antibody and PTRF-eGFP colocalized at the membrane and intracellularly, strongly indicating the presence of caveolae (Fig. 5A) . 2) Using confocal fluorescence and AFM, we verified that spots of PTRF-eGFP fluorescence matched topographical depressions of the plasma membrane in transfected PTRF Ϫ/Ϫ fibroblasts. The fluorescence image of PTRF-eGFP showed a punctuate pattern, whereas the AFM height image revealed a highly corrugated surface (Fig. 5B) . In the overlay of the properly aligned images, we could identify eGFPpositive depressions, indicating caveolae. 3) We demonstrated the presence of caveolae in PTRF-eGFP-transfected PTRF Ϫ/Ϫ fibroblasts by electron microscopy (Fig. 5C) fibroblasts with and without PTRF rescue. The characteristic shape of the basic uptake distribution in each cell type remained unchanged after caveolae had formed (Fig. 6A) . The proportion of CTxB-negative cells, as defined by the 99.9% threshold criterion of untreated cells, was not affected by transfection in both groups (Fig. 6C) . In PTRF ϩ/ϩ and PTRF Ϫ/Ϫ fibroblasts, overexpression of PTRF led to a slight reduction of CTxB intensities (Fig. 6B) . The negative effect of PTRF overexpression on CTxB uptake is consistent with the previously reported finding of reduced CTxB trafficking to the Golgi caused by Cav1 overexpression in wild-type and Cav1 Ϫ/Ϫ mouse embryonic fibroblasts (5) . In contrast, a study of CTxB uptake in Cav1-overexpressing Caco-2 cells, which are otherwise devoid of caveolae, reported no effect (18) . The negative effect of overexpression in the PTRF Ϫ/Ϫ cells might be caused by a general negative side effect of protein overexpression or by the fact that de novo generated caveolae do not contribute to CTxB uptake. Alternatively, a potential negative side effect could mask the positive contribution of caveolae to CTxB uptake.
Although PTRF transfection induces caveolar formation, the role of caveolae in CTxB uptake in PTRF overexpression is unclear. Fluorescence analysis on a subcellular level, as well as distinct uptake characteristics revealed by FACS, strongly suggests a contribution of caveolae to CTxB uptake. Our hypothesis that, upon PTRF rescue in PTRF Ϫ/Ϫ fibroblasts, the uptake characteristics converge to those of control fibroblasts, did not prove true. Our investigation is limited by the fact that we studied human cells only. Suitable animal models would be required to correlate caveolar morphology and function more extensively (7) .
Caveolar function does not correlate well with the presence of the mere "caveolae" as an anatomic structure. Our findings can be interpreted in two ways. 1) The presence of caveolae as an anatomic structure is not sufficient to ensure proper caveolar function. This would be the case in patients with CAV3 mutations, as well as after overexpression of PTRF in our in vitro model.
2) The functional properties assigned to caveolae are mediated by different mechanisms that are yet to be resolved.
